100 percent of Canada is Now Screening Infants for Spinal Muscular Atrophy
We are excited to share that all babies born in Canada can now be tested for spinal muscular atrophy (SMA), a potentially fatal neuromuscular disorder. This milestone has been achieved through the leadership of Muscular Dystrophy Canada (MDC) and is the result of a three-year project working with each Canadian province and territory.
“This initiative holds immense value for the entire Canadian neuromuscular and rare disease community, laying the groundwork for future transformative and life-changing initiatives,” said Dr. Homira Osman, VP of Research and Public Policy, Muscular Dystrophy Canada and Co-Principal Investigator, NMD4C. “There are many progressive neuromuscular disorders where time is of the essence: early diagnosis and prompt access to treatments are critical drivers to achieving the best possible outcomes. MDC will now leverage the knowledge and findings gained from this initiative to ensure other neuromuscular disorders are included in newborn screening programs nationwide.”
Read the full press release from MDC
Highlights of the Press Release:
- This milestone means infants diagnosed with SMA, the most fatal genetic disorder in children under two years of age, can receive life-changing treatment before symptoms even develop.
- It marks the first neuromuscular condition to be added to screening panels across the country.
- The addition of SMA to newborn screening panels in all provinces and territories breaks down barriers and inequities families face simply because of where they live. It also acknowledges that screening for rare genetic diseases and access to early care results in positive health outcomes and long-term cost benefits for everyone.
- In 2020, only Ontario and the Baffin region in Nunavut screened for SMA at birth. Today, regardless of where in Canada a child is born, they will receive the same screening; and, if SMA is diagnosed, the same healthcare, treatment and opportunity to thrive.
For more information please contact:
Homira Osman
Vice-President Research & Public Policy
Muscular Dystrophy Canada
437-912-9037
Read next...
NMD4C 2024 Year in Review
This year in review outlines a collection of achievements from the network over the past year.
NMD4C and MDC Award Fellowship Funding in NMD Research and Medicine
Together the Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are excited to announce the 2025 recipients of our neuromuscular fellowship funding competition to award postdoctoral fellowships in neuromuscular disease (NMD) research and clinical fellowships in neuromuscular medicine and electromyography!
NMD4C Basic Science Trainee Committee Provides Leadership Opportunity for Next Generation of Neuromuscular Researchers
The newly-formed Basic Science Trainee Committee represents the interests of trainees within the network, offering an opportunity for professional growth for future leaders in neuromuscular research.
NMD4C and MDC Host Second SMA Outcome Measure Training Workshop for Physiotherapists and Occupational Therapists Across Canada
The Spinal Muscular Atrophy (SMA) Motor Function Measures workshop organized by the NMD4C in collaboration with MDC took place in Montreal, Quebec on December 3rd, 2024 and was a resounding success. This workshop was established to harmonize assessment practices for the following SMA outcome measures across Canada
NMD4C Launch New Multi-Disciplinary Care of Neuromuscular Diseases Education Curriculum
The NMD4C is excited to share a new training and education initiative from our education team! The Multi-Disciplinary Care of Neuromuscular Diseases lecture series is a new CPD-Accredited 24-topic webinar series designed as an advanced curriculum for the practicing clinical audience to learn fundamentals of multi-disciplinary care for patients across a range of neuromuscular conditions.
